nodes	percent_of_prediction	percent_of_DWPC	metapath
Plerixafor—Induration—Bleomycin—lymphatic system cancer	0.034	0.034	CcSEcCtD
Plerixafor—Platelet count decreased—Mitoxantrone—lymphatic system cancer	0.0207	0.0207	CcSEcCtD
Plerixafor—Haemoglobin—Mechlorethamine—lymphatic system cancer	0.0161	0.0161	CcSEcCtD
Plerixafor—Haemorrhage—Mechlorethamine—lymphatic system cancer	0.0161	0.0161	CcSEcCtD
Plerixafor—Injection site reaction—Carmustine—lymphatic system cancer	0.0132	0.0132	CcSEcCtD
Plerixafor—Musculoskeletal pain—Vincristine—lymphatic system cancer	0.0128	0.0128	CcSEcCtD
Plerixafor—Haemoglobin—Teniposide—lymphatic system cancer	0.0119	0.0119	CcSEcCtD
Plerixafor—Haemorrhage—Teniposide—lymphatic system cancer	0.0118	0.0118	CcSEcCtD
Plerixafor—Unspecified disorder of skin and subcutaneous tissue—Mechlorethamine—lymphatic system cancer	0.0118	0.0118	CcSEcCtD
Plerixafor—Anaphylactic shock—Mechlorethamine—lymphatic system cancer	0.0114	0.0114	CcSEcCtD
Plerixafor—Skin disorder—Mechlorethamine—lymphatic system cancer	0.0111	0.0111	CcSEcCtD
Plerixafor—Swelling—Carmustine—lymphatic system cancer	0.0109	0.0109	CcSEcCtD
Plerixafor—Haemoglobin—Fludarabine—lymphatic system cancer	0.0105	0.0105	CcSEcCtD
Plerixafor—Haemorrhage—Fludarabine—lymphatic system cancer	0.0104	0.0104	CcSEcCtD
Plerixafor—Swelling—Mitoxantrone—lymphatic system cancer	0.0101	0.0101	CcSEcCtD
Plerixafor—Hypersensitivity—Mechlorethamine—lymphatic system cancer	0.00841	0.00841	CcSEcCtD
Plerixafor—Ill-defined disorder—Fludarabine—lymphatic system cancer	0.0084	0.0084	CcSEcCtD
Plerixafor—Malaise—Fludarabine—lymphatic system cancer	0.00817	0.00817	CcSEcCtD
Plerixafor—Hyperhidrosis—Teniposide—lymphatic system cancer	0.00813	0.00813	CcSEcCtD
Plerixafor—Pruritus—Mechlorethamine—lymphatic system cancer	0.00807	0.00807	CcSEcCtD
Plerixafor—Diarrhoea—Mechlorethamine—lymphatic system cancer	0.00781	0.00781	CcSEcCtD
Plerixafor—Arthralgia—Fludarabine—lymphatic system cancer	0.00771	0.00771	CcSEcCtD
Plerixafor—Haemoglobin—Bleomycin—lymphatic system cancer	0.00767	0.00767	CcSEcCtD
Plerixafor—Haemorrhage—Bleomycin—lymphatic system cancer	0.00763	0.00763	CcSEcCtD
Plerixafor—Discomfort—Fludarabine—lymphatic system cancer	0.00762	0.00762	CcSEcCtD
Plerixafor—Dyspnoea—Teniposide—lymphatic system cancer	0.0075	0.0075	CcSEcCtD
Plerixafor—Anaphylactic shock—Fludarabine—lymphatic system cancer	0.00739	0.00739	CcSEcCtD
Plerixafor—Vomiting—Mechlorethamine—lymphatic system cancer	0.00725	0.00725	CcSEcCtD
Plerixafor—Nervous system disorder—Fludarabine—lymphatic system cancer	0.00725	0.00725	CcSEcCtD
Plerixafor—Rash—Mechlorethamine—lymphatic system cancer	0.00719	0.00719	CcSEcCtD
Plerixafor—Dermatitis—Mechlorethamine—lymphatic system cancer	0.00719	0.00719	CcSEcCtD
Plerixafor—Hyperhidrosis—Fludarabine—lymphatic system cancer	0.00715	0.00715	CcSEcCtD
Plerixafor—Feeling abnormal—Teniposide—lymphatic system cancer	0.00693	0.00693	CcSEcCtD
Plerixafor—Gastrointestinal pain—Teniposide—lymphatic system cancer	0.00688	0.00688	CcSEcCtD
Plerixafor—Nausea—Mechlorethamine—lymphatic system cancer	0.00678	0.00678	CcSEcCtD
Plerixafor—Musculoskeletal discomfort—Fludarabine—lymphatic system cancer	0.00674	0.00674	CcSEcCtD
Plerixafor—Haemoglobin—Carmustine—lymphatic system cancer	0.00669	0.00669	CcSEcCtD
Plerixafor—Urticaria—Teniposide—lymphatic system cancer	0.00668	0.00668	CcSEcCtD
Plerixafor—Haemorrhage—Carmustine—lymphatic system cancer	0.00666	0.00666	CcSEcCtD
Plerixafor—Abdominal pain—Teniposide—lymphatic system cancer	0.00665	0.00665	CcSEcCtD
Plerixafor—Erythema—Bleomycin—lymphatic system cancer	0.00664	0.00664	CcSEcCtD
Plerixafor—Paraesthesia—Fludarabine—lymphatic system cancer	0.00664	0.00664	CcSEcCtD
Plerixafor—Dyspnoea—Fludarabine—lymphatic system cancer	0.00659	0.00659	CcSEcCtD
Plerixafor—Connective tissue disorder—Carmustine—lymphatic system cancer	0.00654	0.00654	CcSEcCtD
Plerixafor—Dyspepsia—Fludarabine—lymphatic system cancer	0.00651	0.00651	CcSEcCtD
Plerixafor—Gastrointestinal disorder—Fludarabine—lymphatic system cancer	0.00638	0.00638	CcSEcCtD
Plerixafor—Fatigue—Fludarabine—lymphatic system cancer	0.00637	0.00637	CcSEcCtD
Plerixafor—Inflammation—Methotrexate—lymphatic system cancer	0.00633	0.00633	CcSEcCtD
Plerixafor—Constipation—Fludarabine—lymphatic system cancer	0.00632	0.00632	CcSEcCtD
Plerixafor—Pain—Fludarabine—lymphatic system cancer	0.00632	0.00632	CcSEcCtD
Plerixafor—Connective tissue disorder—Vincristine—lymphatic system cancer	0.00625	0.00625	CcSEcCtD
Plerixafor—Haemoglobin—Mitoxantrone—lymphatic system cancer	0.00622	0.00622	CcSEcCtD
Plerixafor—Hypersensitivity—Teniposide—lymphatic system cancer	0.0062	0.0062	CcSEcCtD
Plerixafor—Haemorrhage—Mitoxantrone—lymphatic system cancer	0.00619	0.00619	CcSEcCtD
Plerixafor—Ill-defined disorder—Bleomycin—lymphatic system cancer	0.00616	0.00616	CcSEcCtD
Plerixafor—Feeling abnormal—Fludarabine—lymphatic system cancer	0.00609	0.00609	CcSEcCtD
Plerixafor—Asthenia—Teniposide—lymphatic system cancer	0.00604	0.00604	CcSEcCtD
Plerixafor—Malaise—Bleomycin—lymphatic system cancer	0.00599	0.00599	CcSEcCtD
Plerixafor—Pruritus—Teniposide—lymphatic system cancer	0.00595	0.00595	CcSEcCtD
Plerixafor—Mental disorder—Carmustine—lymphatic system cancer	0.00583	0.00583	CcSEcCtD
Plerixafor—Erythema—Carmustine—lymphatic system cancer	0.0058	0.0058	CcSEcCtD
Plerixafor—Diarrhoea—Teniposide—lymphatic system cancer	0.00576	0.00576	CcSEcCtD
Plerixafor—Discomfort—Bleomycin—lymphatic system cancer	0.00559	0.00559	CcSEcCtD
Plerixafor—Mental disorder—Vincristine—lymphatic system cancer	0.00557	0.00557	CcSEcCtD
Plerixafor—Hypersensitivity—Fludarabine—lymphatic system cancer	0.00545	0.00545	CcSEcCtD
Plerixafor—Anaphylactic shock—Bleomycin—lymphatic system cancer	0.00542	0.00542	CcSEcCtD
Plerixafor—Erythema—Mitoxantrone—lymphatic system cancer	0.00539	0.00539	CcSEcCtD
Plerixafor—Vomiting—Teniposide—lymphatic system cancer	0.00535	0.00535	CcSEcCtD
Plerixafor—Asthenia—Fludarabine—lymphatic system cancer	0.0053	0.0053	CcSEcCtD
Plerixafor—Rash—Teniposide—lymphatic system cancer	0.0053	0.0053	CcSEcCtD
Plerixafor—Dermatitis—Teniposide—lymphatic system cancer	0.0053	0.0053	CcSEcCtD
Plerixafor—Headache—Teniposide—lymphatic system cancer	0.00527	0.00527	CcSEcCtD
Plerixafor—Pruritus—Fludarabine—lymphatic system cancer	0.00523	0.00523	CcSEcCtD
Plerixafor—Diarrhoea—Fludarabine—lymphatic system cancer	0.00506	0.00506	CcSEcCtD
Plerixafor—Ill-defined disorder—Mitoxantrone—lymphatic system cancer	0.005	0.005	CcSEcCtD
Plerixafor—Nausea—Teniposide—lymphatic system cancer	0.005	0.005	CcSEcCtD
Plerixafor—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.00494	0.00494	CcSEcCtD
Plerixafor—Paraesthesia—Bleomycin—lymphatic system cancer	0.00487	0.00487	CcSEcCtD
Plerixafor—Malaise—Mitoxantrone—lymphatic system cancer	0.00486	0.00486	CcSEcCtD
Plerixafor—Dyspnoea—Bleomycin—lymphatic system cancer	0.00483	0.00483	CcSEcCtD
Plerixafor—Vomiting—Fludarabine—lymphatic system cancer	0.0047	0.0047	CcSEcCtD
Plerixafor—Rash—Fludarabine—lymphatic system cancer	0.00466	0.00466	CcSEcCtD
Plerixafor—Dermatitis—Fludarabine—lymphatic system cancer	0.00466	0.00466	CcSEcCtD
Plerixafor—Pain—Bleomycin—lymphatic system cancer	0.00464	0.00464	CcSEcCtD
Plerixafor—Headache—Fludarabine—lymphatic system cancer	0.00463	0.00463	CcSEcCtD
Plerixafor—Arthralgia—Mitoxantrone—lymphatic system cancer	0.00459	0.00459	CcSEcCtD
Plerixafor—Discomfort—Mitoxantrone—lymphatic system cancer	0.00453	0.00453	CcSEcCtD
Plerixafor—Anaphylactic shock—Vincristine—lymphatic system cancer	0.00452	0.00452	CcSEcCtD
Plerixafor—Feeling abnormal—Bleomycin—lymphatic system cancer	0.00447	0.00447	CcSEcCtD
Plerixafor—Nervous system disorder—Vincristine—lymphatic system cancer	0.00443	0.00443	CcSEcCtD
Plerixafor—Anaphylactic shock—Mitoxantrone—lymphatic system cancer	0.0044	0.0044	CcSEcCtD
Plerixafor—Nausea—Fludarabine—lymphatic system cancer	0.00439	0.00439	CcSEcCtD
Plerixafor—Hyperhidrosis—Vincristine—lymphatic system cancer	0.00437	0.00437	CcSEcCtD
Plerixafor—Shock—Mitoxantrone—lymphatic system cancer	0.00433	0.00433	CcSEcCtD
Plerixafor—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.00431	0.00431	CcSEcCtD
Plerixafor—Urticaria—Bleomycin—lymphatic system cancer	0.00431	0.00431	CcSEcCtD
Plerixafor—Insomnia—Carmustine—lymphatic system cancer	0.00428	0.00428	CcSEcCtD
Plerixafor—Skin disorder—Mitoxantrone—lymphatic system cancer	0.00427	0.00427	CcSEcCtD
Plerixafor—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.00425	0.00425	CcSEcCtD
Plerixafor—Paraesthesia—Carmustine—lymphatic system cancer	0.00425	0.00425	CcSEcCtD
Plerixafor—Dyspnoea—Carmustine—lymphatic system cancer	0.00422	0.00422	CcSEcCtD
Plerixafor—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.00412	0.00412	CcSEcCtD
Plerixafor—Insomnia—Vincristine—lymphatic system cancer	0.00409	0.00409	CcSEcCtD
Plerixafor—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.00408	0.00408	CcSEcCtD
Plerixafor—Paraesthesia—Vincristine—lymphatic system cancer	0.00406	0.00406	CcSEcCtD
Plerixafor—Pain—Carmustine—lymphatic system cancer	0.00405	0.00405	CcSEcCtD
Plerixafor—Constipation—Carmustine—lymphatic system cancer	0.00405	0.00405	CcSEcCtD
Plerixafor—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.00401	0.00401	CcSEcCtD
Plerixafor—Hypersensitivity—Bleomycin—lymphatic system cancer	0.00399	0.00399	CcSEcCtD
Plerixafor—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.00395	0.00395	CcSEcCtD
Plerixafor—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.00392	0.00392	CcSEcCtD
Plerixafor—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.0039	0.0039	CcSEcCtD
Plerixafor—Feeling abnormal—Carmustine—lymphatic system cancer	0.0039	0.0039	CcSEcCtD
Plerixafor—Fatigue—Vincristine—lymphatic system cancer	0.00389	0.00389	CcSEcCtD
Plerixafor—Asthenia—Bleomycin—lymphatic system cancer	0.00389	0.00389	CcSEcCtD
Plerixafor—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.00387	0.00387	CcSEcCtD
Plerixafor—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.00387	0.00387	CcSEcCtD
Plerixafor—Pain—Vincristine—lymphatic system cancer	0.00386	0.00386	CcSEcCtD
Plerixafor—Constipation—Vincristine—lymphatic system cancer	0.00386	0.00386	CcSEcCtD
Plerixafor—Pruritus—Bleomycin—lymphatic system cancer	0.00383	0.00383	CcSEcCtD
Plerixafor—Fatigue—Mitoxantrone—lymphatic system cancer	0.00379	0.00379	CcSEcCtD
Plerixafor—Constipation—Mitoxantrone—lymphatic system cancer	0.00376	0.00376	CcSEcCtD
Plerixafor—Pain—Mitoxantrone—lymphatic system cancer	0.00376	0.00376	CcSEcCtD
Plerixafor—Abdominal pain—Carmustine—lymphatic system cancer	0.00374	0.00374	CcSEcCtD
Plerixafor—Abdominal discomfort—Methotrexate—lymphatic system cancer	0.00369	0.00369	CcSEcCtD
Plerixafor—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.00369	0.00369	CcSEcCtD
Plerixafor—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.00362	0.00362	CcSEcCtD
Plerixafor—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.0036	0.0036	CcSEcCtD
Plerixafor—Abdominal pain—Vincristine—lymphatic system cancer	0.00357	0.00357	CcSEcCtD
Plerixafor—Urticaria—Mitoxantrone—lymphatic system cancer	0.00349	0.00349	CcSEcCtD
Plerixafor—Hypersensitivity—Carmustine—lymphatic system cancer	0.00349	0.00349	CcSEcCtD
Plerixafor—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.00348	0.00348	CcSEcCtD
Plerixafor—Vomiting—Bleomycin—lymphatic system cancer	0.00345	0.00345	CcSEcCtD
Plerixafor—Rash—Bleomycin—lymphatic system cancer	0.00342	0.00342	CcSEcCtD
Plerixafor—Dermatitis—Bleomycin—lymphatic system cancer	0.00341	0.00341	CcSEcCtD
Plerixafor—Asthenia—Carmustine—lymphatic system cancer	0.00339	0.00339	CcSEcCtD
Plerixafor—Hypersensitivity—Vincristine—lymphatic system cancer	0.00333	0.00333	CcSEcCtD
Plerixafor—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.00324	0.00324	CcSEcCtD
Plerixafor—Asthenia—Vincristine—lymphatic system cancer	0.00324	0.00324	CcSEcCtD
Plerixafor—Diarrhoea—Carmustine—lymphatic system cancer	0.00324	0.00324	CcSEcCtD
Plerixafor—Nausea—Bleomycin—lymphatic system cancer	0.00322	0.00322	CcSEcCtD
Plerixafor—Asthenia—Mitoxantrone—lymphatic system cancer	0.00316	0.00316	CcSEcCtD
Plerixafor—Dizziness—Carmustine—lymphatic system cancer	0.00313	0.00313	CcSEcCtD
Plerixafor—Haemoglobin—Methotrexate—lymphatic system cancer	0.0031	0.0031	CcSEcCtD
Plerixafor—Diarrhoea—Vincristine—lymphatic system cancer	0.00309	0.00309	CcSEcCtD
Plerixafor—Haemorrhage—Methotrexate—lymphatic system cancer	0.00308	0.00308	CcSEcCtD
Plerixafor—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.00301	0.00301	CcSEcCtD
Plerixafor—Vomiting—Carmustine—lymphatic system cancer	0.00301	0.00301	CcSEcCtD
Plerixafor—Dizziness—Vincristine—lymphatic system cancer	0.00299	0.00299	CcSEcCtD
Plerixafor—Rash—Carmustine—lymphatic system cancer	0.00298	0.00298	CcSEcCtD
Plerixafor—Dermatitis—Carmustine—lymphatic system cancer	0.00298	0.00298	CcSEcCtD
Plerixafor—Headache—Carmustine—lymphatic system cancer	0.00296	0.00296	CcSEcCtD
Plerixafor—Vomiting—Vincristine—lymphatic system cancer	0.00287	0.00287	CcSEcCtD
Plerixafor—Rash—Vincristine—lymphatic system cancer	0.00285	0.00285	CcSEcCtD
Plerixafor—Dermatitis—Vincristine—lymphatic system cancer	0.00285	0.00285	CcSEcCtD
Plerixafor—Headache—Vincristine—lymphatic system cancer	0.00283	0.00283	CcSEcCtD
Plerixafor—Nausea—Carmustine—lymphatic system cancer	0.00281	0.00281	CcSEcCtD
Plerixafor—Vomiting—Mitoxantrone—lymphatic system cancer	0.0028	0.0028	CcSEcCtD
Plerixafor—Immune system disorder—Methotrexate—lymphatic system cancer	0.00279	0.00279	CcSEcCtD
Plerixafor—Rash—Mitoxantrone—lymphatic system cancer	0.00277	0.00277	CcSEcCtD
Plerixafor—Dermatitis—Mitoxantrone—lymphatic system cancer	0.00277	0.00277	CcSEcCtD
Plerixafor—Headache—Mitoxantrone—lymphatic system cancer	0.00276	0.00276	CcSEcCtD
Plerixafor—Mental disorder—Methotrexate—lymphatic system cancer	0.0027	0.0027	CcSEcCtD
Plerixafor—Erythema—Methotrexate—lymphatic system cancer	0.00269	0.00269	CcSEcCtD
Plerixafor—Nausea—Vincristine—lymphatic system cancer	0.00268	0.00268	CcSEcCtD
Plerixafor—Nausea—Mitoxantrone—lymphatic system cancer	0.00261	0.00261	CcSEcCtD
Plerixafor—Ill-defined disorder—Methotrexate—lymphatic system cancer	0.00249	0.00249	CcSEcCtD
Plerixafor—Malaise—Methotrexate—lymphatic system cancer	0.00242	0.00242	CcSEcCtD
Plerixafor—Arthralgia—Methotrexate—lymphatic system cancer	0.00229	0.00229	CcSEcCtD
Plerixafor—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	0.00227	0.00227	CcSEcCtD
Plerixafor—Discomfort—Methotrexate—lymphatic system cancer	0.00226	0.00226	CcSEcCtD
Plerixafor—Anaphylactic shock—Methotrexate—lymphatic system cancer	0.00219	0.00219	CcSEcCtD
Plerixafor—Nervous system disorder—Methotrexate—lymphatic system cancer	0.00215	0.00215	CcSEcCtD
Plerixafor—Skin disorder—Methotrexate—lymphatic system cancer	0.00213	0.00213	CcSEcCtD
Plerixafor—Hyperhidrosis—Methotrexate—lymphatic system cancer	0.00212	0.00212	CcSEcCtD
Plerixafor—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.002	0.002	CcSEcCtD
Plerixafor—Insomnia—Methotrexate—lymphatic system cancer	0.00198	0.00198	CcSEcCtD
Plerixafor—Paraesthesia—Methotrexate—lymphatic system cancer	0.00197	0.00197	CcSEcCtD
Plerixafor—Dyspnoea—Methotrexate—lymphatic system cancer	0.00195	0.00195	CcSEcCtD
Plerixafor—Dyspepsia—Methotrexate—lymphatic system cancer	0.00193	0.00193	CcSEcCtD
Plerixafor—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.00189	0.00189	CcSEcCtD
Plerixafor—Fatigue—Methotrexate—lymphatic system cancer	0.00189	0.00189	CcSEcCtD
Plerixafor—Pain—Methotrexate—lymphatic system cancer	0.00187	0.00187	CcSEcCtD
Plerixafor—Feeling abnormal—Methotrexate—lymphatic system cancer	0.00181	0.00181	CcSEcCtD
Plerixafor—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.00179	0.00179	CcSEcCtD
Plerixafor—Urticaria—Methotrexate—lymphatic system cancer	0.00174	0.00174	CcSEcCtD
Plerixafor—Abdominal pain—Methotrexate—lymphatic system cancer	0.00173	0.00173	CcSEcCtD
Plerixafor—Hypersensitivity—Methotrexate—lymphatic system cancer	0.00161	0.00161	CcSEcCtD
Plerixafor—Asthenia—Methotrexate—lymphatic system cancer	0.00157	0.00157	CcSEcCtD
Plerixafor—Pruritus—Methotrexate—lymphatic system cancer	0.00155	0.00155	CcSEcCtD
Plerixafor—Diarrhoea—Methotrexate—lymphatic system cancer	0.0015	0.0015	CcSEcCtD
Plerixafor—Dizziness—Methotrexate—lymphatic system cancer	0.00145	0.00145	CcSEcCtD
Plerixafor—Vomiting—Methotrexate—lymphatic system cancer	0.00139	0.00139	CcSEcCtD
Plerixafor—Rash—Methotrexate—lymphatic system cancer	0.00138	0.00138	CcSEcCtD
Plerixafor—Dermatitis—Methotrexate—lymphatic system cancer	0.00138	0.00138	CcSEcCtD
Plerixafor—Headache—Methotrexate—lymphatic system cancer	0.00137	0.00137	CcSEcCtD
Plerixafor—Nausea—Methotrexate—lymphatic system cancer	0.0013	0.0013	CcSEcCtD
